Introgen to Present ADVEXIN Phase 3 Study Results at Cancer Clinical Trials and Personalized Medicine Conference
News Jul 21, 2008
Introgen Therapeutics, Inc. has announced that the company will present the results from its recently completed Phase 3 trial of ADVEXIN in recurrent head and neck cancer at the American Association for Cancer Research (AACR) Centennial Conference on Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine.
The conference will be held July 20-23, 2008 at the Hyatt Regency Monterey in Monterey, CA.
Introgen’s presentation will review the previously announced findings from the Company’s Phase 3 trial which demonstrated that ADVEXIN successfully achieved its primary and secondary efficacy endpoints in the study’s pre-specified p53 biomarker population.
In addition, Introgen will present supplemental statistical analyses that are included in the Company’s Biologics License Application and Marketing Authorization Application in the U.S. and Europe, respectively.
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Retrained Enzyme is Biocatalysis MilestoneNews
TU Graz researchers managed for the first time ever to ‘retrain’ an enzyme to build ring-shaped molecular structures instead of performing its natural task of reducing double bonds. The work was published in Angewandte Chemie, and is relevant for the production of pharmaceuticals and plant protection products.
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018